A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy.

ABSTRACT:

Background

Many men develop a rising PSA after initial therapy for prostate cancer. While some of these men will develop a local or metastatic recurrence that warrants further therapy, others will have no evidence of disease progression. We hypothesized that an expression biomarker panel can predict which men with a rising PSA would benefit from further therapy.

Methodology/principal findings

A case-control design was used to test the association of gene expression with outcome. Systemic (SYS) progression cases were men post-prostatectomy who developed systemic progression within 5 years after PSA recurrence. PSA progression controls were matched men post-prostatectomy with PSA recurrence but no evidence of clinical progression within 5 years. Using expression arrays optimiz

SUBMITTER: Nakagawa T 

PROVIDER: S-EPMC2565588 | biostudies-literature | 2008

REPOSITORIES: biostudies-literature